Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

AEON Biopharma, Inc.

Healthcare US AEON

0.7315USD
-0.0187(2.49%)

Last update at 2026-06-03T20:00:00Z

Day Range

0.730.74
LowHigh

52 Week Range

0.391.45
LowHigh

Fundamentals

  • Previous Close 0.75
  • Market Cap27.07M
  • Volume8423
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-16.22400M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-3.95

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -39.22200M 42.01M -384.63200M -52.55600M -55.63700M
Minority interest - - - - -
Net income -39.22200M 42.01M -384.63200M -52.55600M -55.63700M
Selling general administrative 12.21M 13.64M - 13.68M 11.15M
Selling and marketing expenses - - - - -
Gross profit -0.07800M - - - -
Reconciled depreciation 0.08M 0.10M - 0.07M 0.00300M
Ebit -16.90200M -27.82400M -52.83600M -48.42900M -7.91500M
Ebitda -16.82400M -27.72700M -52.73700M -48.36100M -7.91200M
Depreciation and amortization 0.08M 0.10M 0.10M 0.07M 0.00300M
Non operating income net other - - - - -
Operating income -16.90200M 72.98M -348.08600M -48.42900M -65.84700M
Other operating expenses 16.90M 72.98M 348.09M 48.43M 36.88M
Interest expense - - - - -
Tax provision 0.00000M 0.00000M - 0.00000M 0.00000M
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - 28.97M
Total revenue 0.00000M 0.00000M - 0.00000M 0.00000M
Total operating expenses 16.82M -72.98500M 348.09M 48.43M 36.88M
Cost of revenue 0.08M - - - -
Total other income expense net -22.32000M -30.98000M -36.54600M -4.12700M -18.75600M
Discontinued operations - - - - -
Net income from continuing ops -39.22200M 42.01M - -52.55600M -55.63700M
Net income applicable to common shares - - - -52.55600M -55.63700M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 5.56M 3.14M 6.84M 10.78M 6.44M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.39M 1.58M 1.06M 0.09M 0.03M
Total liab 60.59M 31.71M 159.89M 281.19M 230.26M
Total stockholder equity -55.02700M -28.56900M -153.04400M -287.50000M -234.94400M
Deferred long term liab - - - - -
Other current liab 5.13M 7.55M 8.81M 3.90M 4.01M
Common stock 0.00900M 0.00400M 0.00400M 0.01M 0.01M
Capital stock 0.00900M 0.00400M 0.00400M 0.01M 0.01M
Retained earnings -470.81900M -431.59700M -473.60200M -474.83900M -422.28300M
Other liab - - - - 0.22M
Good will - - - - -
Other assets - - - 0.03M 0.36M
Cash 3.01M 0.01M 5.16M 9.75M 5.13M
Cash and equivalents - - - - -
Total current liabilities 6.90M 14.15M 13.05M 82.57M 20.80M
Current deferred revenue - - - - -
Net debt 32.74M 12.94M -4.88000M 121.79M 81.76M
Short term debt 0.25M 0.12M 0.28M 70.87M 15.60M
Short long term debt - - - 70.87M 15.60M
Short long term debt total 35.74M 12.96M 0.28M 131.53M 86.89M
Other stockholder equity 415.78M 403.02M 320.55M 187.32M 187.32M
Property plant equipment - - - 0.91M 0.92M
Total current assets 3.40M 1.59M 6.22M 9.84M 5.15M
Long term investments - - - - -
Net tangible assets - - - -287.50000M -234.94400M
Short term investments - - - - -
Net receivables - - - - -
Long term debt 34.60M 11.69M - 60.43M 70.76M
Inventory - - - - -
Accounts payable 0.94M 5.91M 3.39M 7.80M 1.19M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.95M 0.03M 0.03M 0.03M 0.36M
Deferred long term asset charges - - - - -
Non current assets total 2.16M 1.55M 0.62M 0.94M 1.28M
Capital lease obligations 1.15M 1.27M 0.28M 0.24M 0.52M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00000M - -0.30600M -0.17000M
Change to liabilities - - - 6.61M -0.89800M
Total cashflows from investing activities -0.00400M - - -0.30600M -0.17000M
Net borrowings 0.00000M 15.00M - 40.51M 15.00M
Total cash from financing activities 20.30M 15.15M 14.00M 40.51M 13.56M
Change to operating activities - - - -0.34500M 2.31M
Net income -39.22200M 42.01M -384.63200M -52.55600M -55.63700M
Change in cash 2.99M -5.14500M -4.58800M 4.62M -15.04000M
Begin period cash flow 0.01M 5.16M 9.75M 5.13M 20.17M
End period cash flow 3.01M 0.01M 5.16M 9.75M 5.13M
Total cash from operating activities -17.30800M -20.29200M -47.82500M -35.58400M -28.43300M
Issuance of capital stock 18.51M 0.15M - - -
Depreciation 0.08M 0.10M 0.10M 0.07M 0.00300M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 1.79M - - 44.50M 13.56M
Change to netincome - - - 10.64M 25.79M
Capital expenditures 0.00400M 0.00000M 0.00000M 0.31M 0.17M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -6.94100M 0.71M -2.73900M 6.27M 1.42M
Stock based compensation 5.32M 6.25M 7.10M 5.89M 5.22M
Other non cash items 23.46M -69.35000M 339.45M 4.74M 20.57M
Free cash flow -17.31200M -20.29200M -47.82500M -35.89000M -28.60300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AEON
AEON Biopharma, Inc.		 -0.0187 2.49% 0.73 - 1.16 97.16 - 201.68 -5.8898
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

AEON Biopharma, Inc.

5 Park Plaza, Irvine, CA, United States, 92614

Key Executives

Name Title Year Born
Mr. Marc Forth Principal Financial Officer, President, CEO & Director 1971
Mr. Alex Wilson Executive VP, Chief Legal Officer & Corporate Secretary 1987
Dr. Chad K. Oh M.D. Chief Medical Officer 1959
Ms. Jennifer Sy Principal Accounting Officer 1985
Mr. Alex Wilson Chief Legal and Strategy Officer & Corporate Secretary 1987
Dr. Chad K. Oh M.D. Chief Medical Officer 1958
Mr. Robert Bancroft President, CEO & Director 1965
Mr. John A. Bencich M.B.A. Chief Financial Officer 1977
Ms. Jennifer Sy Chief Accounting Officer 1986

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions